UMC119-06

BIOLOGICAL3 trials

Sponsors

Meridigen Biotech Co., Ltd.

Conditions

Acute Ischemic StrokeAcute Respiratory Distress SyndromeChronic Obstructive Pulmonary Disease Moderate

Phase 1

Mesenchymal Stem Cells for The Treatment of Acute Ischemic Stroke

Meridigen Biotech Co., Ltd.Acute Ischemic Stroke

Start: 2019-12-05End: 2025-12-31Target: 9Updated: 2023-12-04

Mesenchymal Stem Cells for The Treatment of Chronic Obstructive Pulmonary Disease

Meridigen Biotech Co., Ltd.Chronic Obstructive Pulmonary Disease Moderate

Start: 2020-06-11End: 2024-06-30Target: 9Updated: 2023-12-04

Mesenchymal Stem Cells for The Treatment of Acute Respiratory Distress Syndrome (ARDS)

Meridigen Biotech Co., Ltd.Acute Respiratory Distress Syndrome

Start: 2024-01-01End: 2025-09-30Target: 18Updated: 2023-12-04

Related Papers

A Phase I, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of Intravenous UMC119-06 in Patients with Acute Ischemic Stroke.

2026-01-01

Late Breaking Abstract - The interim analysis result of allogeneic umbilical cord mesenchymal stem cells administration to moderate COPD patients: an open-label, dose escalation, Phase I study.

2023-09-09